Boehringer’s Japan Sales Up 5.4% in 2020 as Ofev, Jardiance Fare Well

Boehringer Ingelheim’s Japan revenue in 2020 grew 5.4% year on year on the back of strong performances seen with its idiopathic pulmonary fibrosis (IPF) treatment Ofev (nintedanib) and its SGLT2 inhibitor Jardiance (empagliflozin). In the financial year through December, the...read more